Roszdravnadzor has authorized the American company Pfizer to conduct clinical trials of a new drug against the coronavirus Paxlovid in Russia. The Vedomosti newspaper writes about it.
Based on information from the National Medicines Registry, it follows that the drug will be tested on adults who have been in contact with people infected with the coronavirus at home.
The tests will involve 90 people. The study will be carried out in public and private medical institutions in the Moscow region, St. Petersburg, Smolensk, Barnaul and other cities.
A representative of the 39; company clarified that the new drug is being tested worldwide. In total, seven thousand people participate.
It is expected that by the end of this year, Pfizer will launch more than 180 thousand doses of the drug, and in 2022 – and ndash; to increase production to 50 million of the first domestic direct-acting injectable drug for the treatment of COVID-19, Areplivir. In addition, the head of the Ministry of Health of the Russian Federation, Mikhail Murashko, spoke about the development of a national drug that allows to stop the development of COVID-19 at the initial stage.